| 0:00:05 | you know that these where condition diagnosed in approximately one hundred thousand you ones |
|---|
| 0:00:11 | it can you don't yes which results in human or gonna which could use |
|---|
| 0:00:17 | unlike autoimmune these just extremely rare was expensive each |
|---|
| 0:00:21 | you outside this is not an informed i met |
|---|
| 0:00:24 | resulting in slow secondary to get because of development decrease as a mass or it's |
|---|
| 0:00:32 | just function |
|---|
| 0:00:33 | recent advances in molecular genetics have revealed that you involved in this population size |
|---|
| 0:00:40 | well i used is usually |
|---|
| 0:00:44 | by prior to the ice |
|---|
| 0:00:46 | prominent cases of that ids are usually the result of mediation thing at that would |
|---|
| 0:00:52 | test and channel because all |
|---|
| 0:00:55 | the simple understanding of the challenge disease has also allowed us to better management of |
|---|
| 0:01:00 | the ladies |
|---|
| 0:01:02 | well in gender balance remains as a means the treatment in formant ids also tried |
|---|
| 0:01:09 | have simplified to management of patients with mutations in at the top panel of a |
|---|
| 0:01:17 | cell |
|---|
| 0:01:18 | in addition we don't i should go to test for different diagnoses and ensure proper |
|---|
| 0:01:25 | management |
|---|